Does Ozempic cause stomach paralysis? What the data shows

What did @corinne_nnnutrition actually say?

The claim is that "a new study" shows Ozempic causes "stomach paralysis" in "a lot of people," resulting in dangerous buildups of days-old undigested food. She also lists diabetic retinopathy, thyroid cancer, hypoglycemia, pancreatitis, and gallbladder issues as things patients "are experiencing." Then she pivots to a lifestyle coaching pitch, arguing you "cannot get healthier in an environment that made you sick" and that semaglutide will "further prolong those issues."

To be direct: some of this is grounded in real pharmacology, but the framing inflates rare risks into near-certainties, cites a vague "new study" that goes unnamed, and wraps the whole thing in a sales pitch for her coaching services. That combination deserves scrutiny.

Does the science back this up?

Gastroparesis as a serious risk from semaglutide is real but rare, and the data is more complicated than "a lot of people" are getting it. The evidence does not support panic, and it does not support dismissal either.

A 2023 retrospective cohort study published in JAMA by Sodhi et al. looked at over 4,000 GLP-1 receptor agonist users and found a statistically significant increase in gastroparesis risk compared to bupropion-naltrexone users, with an adjusted hazard ratio of around 3.67 for semaglutide specifically. That sounds alarming until you look at absolute numbers: gastroparesis was still rare in both groups. The mechanism makes sense. GLP-1 receptor agonists deliberately slow gastric emptying as part of how they suppress appetite. In most people, that mild delay is the intended effect. In a smaller subset, it appears to tip into clinically significant delayed gastric emptying. The FDA has received case reports, and it is a listed risk in prescribing information. So the kernel of truth is real. The "a lot of people" framing is not.

The other side effects she lists, including pancreatitis, gallbladder disease, and injection site reactions, are documented in prescribing information and clinical trials. Thyroid C-cell tumors appeared in rodent studies but have not been confirmed in human clinical data to date. Diabetic retinopathy worsening has been observed in patients with pre-existing retinopathy who experienced rapid glucose lowering, a nuance she skips entirely.

What did they get wrong (or right)?

She gets credit for raising gastroparesis as a legitimate concern. The Sodhi et al. data is real, the FDA has flagged it, and patients deserve to know. That is genuinely useful information for someone considering semaglutide.

What she gets wrong is the magnitude and framing. Saying "a lot of people" are experiencing stomach paralysis misrepresents the current evidence base, which shows a meaningful relative risk increase but low absolute incidence. She also states that "10% of our food" normally remains in the stomach for hours after digestion as her baseline comparison, which is a garbled version of standard gastric emptying physiology and not how gastroparesis is actually defined clinically.

The claim that semaglutide will "further prolong" underlying health issues is stated as fact with zero clinical evidence. For type 2 diabetes patients specifically, the SUSTAIN and STEP trial series showed cardiovascular and metabolic benefits. Telling overweight people that Ozempic makes their problems worse long term, without qualification, is not supported by the published trial data and could discourage people from discussing a potentially appropriate option with their doctor.

The lifestyle framing is not wrong in isolation. Sustainable behavior change matters. But using inflated risk claims to funnel viewers toward her coaching program is a conflict of interest she does not disclose.

What should you actually know?

Semaglutide does slow gastric emptying by design, and for a subset of patients this becomes clinically problematic. If you have pre-existing gastroparesis or a history of delayed gastric emptying, that is a conversation you need to have with your prescriber before starting any GLP-1 receptor agonist. Full stop.

The side effect list she rattles off is largely accurate as a list, but context matters. Nausea and diarrhea are common. Pancreatitis is rare but serious. Thyroid C-cell tumors are a black box warning based on animal data, not confirmed human cases. These are documented risks in the FDA label, not hidden findings from a whistleblower study. Your doctor should be walking you through them.

What the evidence actually shows, across the STEP trial series (Wilding et al., 2021, NEJM) and cardiovascular outcomes data, is that semaglutide produces clinically meaningful weight loss and, in specific populations, reduces major cardiovascular events. The risk-benefit calculation is not the same for everyone, which is exactly why it requires a licensed prescriber, not a TikTok video in either direction.